Summary: Tocilizumab is a novel monoclonal antibody that competitively inhibits the binding of interleukin-6 (IL-6) to its receptor (IL-6R). Inhibiting the entire receptor complex prevents IL-6 ...

Cells producing interleukin-6 (IL-6) and the actions of IL-6 in the body. Ig = immunoglobulin, CRP = C-reactive protein, SAA = serum amyloid A protein. Reprinted, with permission, from reference 21.

In the phase 3 trial, nemolizumab monotherapy showed rapid and sustained improvements in key signs (skin lesions) and ...

triggers interleukin (IL)-1β secretion via activation of NOD-, LRR- and pyrin domain-containing protein 3 (NLRP3) inflammasome. The objective was to explore the effect of AAT augmentation therapy in ...

Fintel reports that on December 11, 2024, HC Wainwright & Co. downgraded their outlook for AnaptysBio (NasdaqGS:ANAB) from ...

The LAR is associated with prolonged airway hyperresponsiveness and increased eosinophilia. Benralizumab, a monoclonal ...

In an interview with Ophthalmology Times, Alon Kahana, MD, PhD, discusses interleukin-6 and its role in autoimmune diseases, particularly thyroid eye disease, noting that a promising alternative under ...

This study demonstrates the development of PAGERs (programmable antigen-gated engineered receptors), combining antigen ...

Cancer immunotherapy is a therapy used to treat cancer patients that involves or uses components of the immune system. Some cancer immunotherapies consist of antibodies that bind to, and inhibit ...

Charles Schwab Investment Management Inc. raised its position in AnaptysBio, Inc. (NASDAQ:ANAB – Free Report) by 3.2% in the ...

TNF Pharmaceuticals (TNFA) announced that topline results from a Phase 2a study of its lead drug candidate MYMD-1 was presented at a ...

TOUR-006 is a monoclonal antibody commercialized by Tourmaline Bio, with a leading Phase II program in Graves' Ophthalmopathy.